27 news items
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
, 0.9), major adverse cardiovascular events (Year 1, 0.3; Year 4, 0.3), venous thromboembolism (Year 1, 0.2; Year 4, 0.1) and deaths (Year 1, 0.2; Year
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
Lung cancer is the leading cause of cancer deaths globally. Non-small cell lung cancer (NSCLC) is one of the most
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with cisplatin-gemcitabine alone (Hazard Ratio [HR] 0.78; 95% Confidence
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
BMY
12 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
wvx9ssv
BMY
JNJ
MRK
10 Apr 24
and this time round, they are turning to the world’s most common causes of death- cancer and heart disease.
Johnson & Johnson
4ph2rw70rq14s7hz9dwb3dfhoxa1p914zj
BMY
8 Apr 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted
bigso3 9u9iky
BMY
8 Apr 24
for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death
In the pooled safety
n8ytplfj6iq66xu9l3i9fkysrfujf
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
6dro426fbgu qblwbvgc0rh
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
16lpy8f e7q8x
BMY
4 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
vr9kgh8k6m e5a
BMY
2 Apr 24
).
Safety results were consistent with previous MDS studies, and progression to acute myeloid leukemia and total deaths were
mvxukphvp4fi lkk40h
BMY
31 Mar 24
, regarding Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
0mxjeym94eck33ojzpnubyc7kvsqpdb5mr6s dg8d7re1
BMY
27 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
th0pq07ldx4phle3p
BMY
MRK
27 Mar 24
improved multiple secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events by 84% versus
v9jlcjjt41v g81sabdd33d4geczm1sj1ne10lke4v7
ATNM
AZN
BMY
25 Mar 24
-enlarging cysts that impair kidney function, potentially leading to kidney failure or premature death. Currently, an estimated 250,000 individuals
flzezu9fe1wujonls6qlz10xf7f1bm6om3d0477iky3nniytn
BMY
23 Mar 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted
hr1nd7ehna5qmydz9oo718innbuyszczq0m3hxwm2v 56fl4rzuc2
BMY
20 Mar 24
of disease progression or death and a well-established safety profile with mostly low-grade and transient occurrences of cytokine release syndrome
ppoaf6px9fukf2ka8rc1 ol4xxedmwn34
BMY
20 Mar 24
demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well
2xc0 h3c9xcyfps6m9rhfmsl6mltf
BMY
19 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial